Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.90
-1.0%
$8.88
$6.00
$10.94
$2.52B0.575.16 million shs19.03 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$34.09
+0.9%
$32.02
$19.52
$35.79
$2.68B0.95920,719 shs1.14 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$23.35
-1.2%
$22.74
$16.52
$25.15
$1.72B0.35757,629 shs605,582 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
+1.3%
$1.28
$0.98
$1.60
$1.14B1.52.70 million shs1.89 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+7.13%+11.44%+20.31%+4.33%+0.44%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+2.43%+2.58%+9.93%+6.39%+56.03%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.30%+4.42%+5.25%+4.32%+14.31%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+2.05%+5.67%+17.32%+27.35%+15.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.90
-1.0%
$8.88
$6.00
$10.94
$2.52B0.575.16 million shs19.03 million shs
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$34.09
+0.9%
$32.02
$19.52
$35.79
$2.68B0.95920,719 shs1.14 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$23.35
-1.2%
$22.74
$16.52
$25.15
$1.72B0.35757,629 shs605,582 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
+1.3%
$1.28
$0.98
$1.60
$1.14B1.52.70 million shs1.89 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+7.13%+11.44%+20.31%+4.33%+0.44%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
+2.43%+2.58%+9.93%+6.39%+56.03%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.30%+4.42%+5.25%+4.32%+14.31%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+2.05%+5.67%+17.32%+27.35%+15.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.75
Moderate Buy$20.70109.09% Upside
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.82
Moderate Buy$49.3044.62% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
2.57
Moderate Buy$36.2055.03% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.552.65% Upside

Current Analyst Ratings Breakdown

Latest OPK, CLDX, BCRX, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/22/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Reiterated RatingBuy$42.00
6/15/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Reiterated RatingBuy$42.00
6/10/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetBuy$38.00 ➝ $45.00
6/1/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Reiterated RatingHold (C)
6/1/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Reiterated RatingBuy$46.00
5/26/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Reiterated RatingBuy$42.00
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/13/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetOverweight$38.00 ➝ $54.00
5/8/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Boost Price TargetOverweight$45.00 ➝ $48.00
5/7/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Boost Price TargetMarket Outperform$25.00 ➝ $28.00
5/7/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Lower Price TargetOutperform$22.00 ➝ $21.00
(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$885.72M2.84$1.32 per share7.52($0.57) per share-17.37
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$1.54M1,737.48N/AN/A$7.93 per share4.30
Innoviva, Inc. stock logo
INVA
Innoviva
$411.33M4.19$4.99 per share4.68$15.71 per share1.49
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.88N/AN/A$1.67 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.78N/A30.94N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$6.013.899.89N/A119.89%33.33%22.67%8/5/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)

Latest OPK, CLDX, BCRX, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million
5/6/2026Q1 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million
5/6/2026Q1 2026
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43$0.44+$0.01$2.22$101.57 million$97.99 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
1.91
1.88
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
8.92
8.92
Innoviva, Inc. stock logo
INVA
Innoviva
0.19
21.13
20.07
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
5.20%
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530254.16 million244.51 millionOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15078.49 million74.41 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10073.81 million72.33 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable

Recent News About These Companies

Spotlight On Promising Penny Stocks For May 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.90 -0.10 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$9.98 +0.08 (+0.81%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$34.09 +0.31 (+0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$34.10 +0.00 (+0.01%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Innoviva stock logo

Innoviva NASDAQ:INVA

$23.35 -0.29 (-1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$23.34 -0.01 (-0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.51 +0.02 (+1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 -0.01 (-0.33%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.